Table 4.

Concordance between the number of mutations detected in plasma at the time of initial diagnosis and detection of metastasis

ccfDNA mutations at the time of primary versus metastatic disease
Patient	Disease	Gain of mutations after metastasis	Loss of mutations after metastasis	Time to metastasis [months]
1	colon AC	40% (4/10)	38% (5/14)	70
2	colon AC	64% (7/11)	20% (1/5)	20
3	colon AC	40% (2/5)	77% (10/13)	12
4	colon AC	0% (0/1) ˆ	92% (12/13)	5
5	colon AC	25% (1/4)	0% (0/3)	1
average		33.8%	45.4%	21.6
6	PDAC	38% (3/8)	58% (7/12)	16
7	PDAC	67% (2/3)	89% (8/9)	9
8	PDAC	80% (4/5)	86% (6/7)	18
9	PDAC	58% (7/12)	38% (3/8)	15
10	PDAC	70% (7/10)	25% (1/4)	7
average		62.6%	59.2%	13

AC, adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma

^ˆhemolysis and wildtype cellular DNA contamination